Thrivent Financial for Lutherans
INO icon

Thrivent Financial for Lutherans’s Inovio Pharmaceuticals INO Stock Holding History

Thrivent Financial for Lutherans’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,667
Closed -$10K – 2556
2023
Q4 		$10K Hold
1,667
– – ﹤0.01% 2477
2023
Q3 		$8K Hold
1,667
– – ﹤0.01% 2425
2023
Q2 		$9K Buy
+1,667
New +$13.4K ﹤0.01% 2455
2021
Q1 		– Sell
-11,962
Closed -$1.27M – 2544
2020
Q4 		$1.27M Buy
+11,962
New +$1.59M ﹤0.01% 1604

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Thrivent Financial for Lutherans's INO Position: Q1 2024 in Review

Thrivent Financial for Lutherans sold out of Inovio Pharmaceuticals (INO) in Q1 2024, closing a stake of 1,667 shares — an estimated $10K sold.

Thrivent Financial for Lutherans first reported a position in INO in Q4 2020 and held it in 4 quarters. The position peaked at $1.27M in Q4 2020. 89 funds tracked by Wall St. Rank hold INO as of Q1 2024.

  • Thrivent Financial for Lutherans reported no remaining Inovio Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 1,667 Inovio Pharmaceuticals shares in Q1 2024, an estimated $10K.
  • Thrivent Financial for Lutherans first reported a position in Inovio Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Thrivent Financial for Lutherans's Inovio Pharmaceuticals position peaked at $1.27M in Q4 2020.
  • 89 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2024.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2024, filed 14 May 2024.